How is Lartruvo administered?

The approved recommended dosage of Lartruvo is 15 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion given over 60 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.

Patients should be premedicated with diphenhydramine (25 to 50 mg intravenously) and dexamethasone (10 to 20 mg intravenously), prior to Lartruvo on Day 1 of cycle 1. For the first 8 cycles, Lartruvo is administered with doxorubicin. Refer to doxorubicin prescribing information for dosing, and dose modifications.

Lartruvo (olaratumab) injection is used in combination with doxorubicin for the treatment of adult patients with soft tissue sarcoma (STS) who cannot be cured with radiation or surgery. The soft tissue sarcoma is a histologic subtype for which an anthracycline-containing regimen is appropriate.

Learn more: What is Soft Tissue Sarcoma?

How does Lartruvo work?

Lartruvo works as a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody to help slow or stop tumor growth.

In clinical studies submitted to the FDA, Lartruvo was shown to lengthen survival time. Patients who received Lartruvo with doxorubicin had a statistically significant improvement in overall survival: the median survival was 26.5 months compared to 14.7 months for patients who received doxorubicin alone.

Common side effects included nausea, fatigue, low white blood cells (neutropenia), and muscle pain, among others.

This is not all the information you need to know about Lartruvo (olaratumab) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Lartruvo information here, and discuss this information and any questions you have with your doctor or other health care provider.